Thrombosis UK has said proposed guidance from the National Institute for Health and Care Excellence on the management of atrial fibrillation reflected a “lack of consideration” of patient safety issues.
A UK charity has expressed patient safety concerns over draft guidance issued by the National Institute for Health and Care Excellence (NICE) on the management of atrial fibrillation (AF).
Thrombosis UK told The Pharmaceutical Journal that the proposed guidance reflected a “lack of consideration” of the issues that affect patient safety, such as renal dose adjustment, drug interactions, age and bodyweight dose adjustment.
Read the full article at: https://www.pharmaceutical-journal.com
